Cargando…

Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19

PURPOSE: SARS-CoV-2 is a new pandemic influenza caused by a coronavirus which main route of transmission is through exhaled droplets that primarily infect the nose and the nasopharynx. The aim of this paper is to evaluate the effect of acetic acid, the active component of vinegar, as a potential dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Pianta, L., Vinciguerra, A., Bertazzoni, G., Morello, R., Mangiatordi, F., Lund, V. J., Trimarchi, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245632/
https://www.ncbi.nlm.nih.gov/pubmed/32449022
http://dx.doi.org/10.1007/s00405-020-06067-8
_version_ 1783537783132913664
author Pianta, L.
Vinciguerra, A.
Bertazzoni, G.
Morello, R.
Mangiatordi, F.
Lund, V. J.
Trimarchi, M.
author_facet Pianta, L.
Vinciguerra, A.
Bertazzoni, G.
Morello, R.
Mangiatordi, F.
Lund, V. J.
Trimarchi, M.
author_sort Pianta, L.
collection PubMed
description PURPOSE: SARS-CoV-2 is a new pandemic influenza caused by a coronavirus which main route of transmission is through exhaled droplets that primarily infect the nose and the nasopharynx. The aim of this paper is to evaluate the effect of acetic acid, the active component of vinegar, as a potential disinfectant agent for upper airways. METHODS: Twenty-nine patients were enrolled and divided into two groups: group 1 (14 patients) was composed of patients treated with off-label hydroxychloroquine and lopinavir/ritonavir, whereas group 2 (15 patients) was composed of patients treated with hydroxychloroquine only, combined with the inhalation of acetic acid disinfectant at a 0.34% concentration. A questionnaire-based evaluation of symptoms was performed after 15 days in both groups. RESULTS: It appears that the number of patients treated with acetic acid (group 2) that experienced improvement in individual symptoms was double that of the other group of patients (group 1), although numbers are too small for robust statistical analysis. CONCLUSIONS: Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation.
format Online
Article
Text
id pubmed-7245632
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72456322020-05-26 Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19 Pianta, L. Vinciguerra, A. Bertazzoni, G. Morello, R. Mangiatordi, F. Lund, V. J. Trimarchi, M. Eur Arch Otorhinolaryngol Short Communication PURPOSE: SARS-CoV-2 is a new pandemic influenza caused by a coronavirus which main route of transmission is through exhaled droplets that primarily infect the nose and the nasopharynx. The aim of this paper is to evaluate the effect of acetic acid, the active component of vinegar, as a potential disinfectant agent for upper airways. METHODS: Twenty-nine patients were enrolled and divided into two groups: group 1 (14 patients) was composed of patients treated with off-label hydroxychloroquine and lopinavir/ritonavir, whereas group 2 (15 patients) was composed of patients treated with hydroxychloroquine only, combined with the inhalation of acetic acid disinfectant at a 0.34% concentration. A questionnaire-based evaluation of symptoms was performed after 15 days in both groups. RESULTS: It appears that the number of patients treated with acetic acid (group 2) that experienced improvement in individual symptoms was double that of the other group of patients (group 1), although numbers are too small for robust statistical analysis. CONCLUSIONS: Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation. Springer Berlin Heidelberg 2020-05-24 2020 /pmc/articles/PMC7245632/ /pubmed/32449022 http://dx.doi.org/10.1007/s00405-020-06067-8 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Short Communication
Pianta, L.
Vinciguerra, A.
Bertazzoni, G.
Morello, R.
Mangiatordi, F.
Lund, V. J.
Trimarchi, M.
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title_full Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title_fullStr Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title_full_unstemmed Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title_short Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
title_sort acetic acid disinfection as a potential adjunctive therapy for non-severe covid-19
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245632/
https://www.ncbi.nlm.nih.gov/pubmed/32449022
http://dx.doi.org/10.1007/s00405-020-06067-8
work_keys_str_mv AT piantal aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT vinciguerraa aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT bertazzonig aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT morellor aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT mangiatordif aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT lundvj aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19
AT trimarchim aceticaciddisinfectionasapotentialadjunctivetherapyfornonseverecovid19